Drug
Fxs887
Fxs887: highest development phase Phase 1, developed by Shanghai Fosun Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FXS887 NCT07345637 | Phase 1 | Solid Tumor Refractory to Conventional Treatment |
Latest
No recent events.
Follow Fxs887 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.